These are the first results for lambrolizumab (MK-3475), which is Merck’s investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma.
Bristol Myers Squibb is developing nivolumab, an anti-PD-1 antibody. Merck has lambrolizumab, and Roche is developing anti-PD-L1 antibody MPDL3280A. Analyst estimates for Roche's drug, seen as a ...
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin ...
A large “de-escalation” trial suggests that tens of thousands of people annually may be able to rely on only chemotherapy and surgery to treat their illness. By Gina Kolata For some patients ...